This review evaluates 30+ analytical methods for quantifying raltegravir in pharmaceutical formulations, highlighting their efficacy.
Raltegravir, an integrase strand transfer inhibitor (INSTI), is the first FDA-approved drug in its class for HIV therapy.Due to its clinical significance, a variety of analytical methods have been developed for its quantification in pharmaceutical formulations and biological matrices. This review comprehensively compiles 30+ analytical techniques including UV spectrophotometry,RPHPLC, HPTLC, UPLC, LC-MS/MS, and electrochemical methods, evaluating their sensitivity, specificity, and validation status.The aim is to guide researchers in selecting suitable methods for routine, pharmacokinetic,and stability analysis of Raltegravir.
No takes yet. Share an insight, caveat, or question.
Kumar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: